WW 15 Pill - white round, 9mm
Pill with imprint WW 15 is White, Round and has been identified as Glycopyrrolate 1 mg. It is supplied by West-Ward Pharmaceutical Corporation.
Glycopyrrolate is used in the treatment of Anesthesia; Excessive Salivation; Peptic Ulcer; COPD, Maintenance and belongs to the drug classes anticholinergic bronchodilators, anticholinergics/antispasmodics. There is no proven risk in humans during pregnancy. Glycopyrrolate 1 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WW 15
Glycopyrrolate
- Imprint
- WW 15
- Strength
- 1 mg
- Color
- White
- Size
- 9.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Anticholinergic bronchodilators, Anticholinergics/antispasmodics
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- West-Ward Pharmaceutical Corporation
- National Drug Code (NDC)
- 00143-1250 (Discontinued)
- Inactive Ingredients
-
calcium phosphate dibasic anhydrous,
lactose anhydrous,
lactose monohydrate,
magnesium stearate,
povidone k30,
sodium starch glycolate type A potato
Note: Inactive ingredients may vary.
Related images for "WW 15"
More about glycopyrrolate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (18)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: anticholinergic bronchodilators
- Breastfeeding
Patient resources
- Glycopyrrolate drug information
- Glycopyrrolate inhalation
- Glycopyrrolate (Inhalation) (Advanced Reading)
- Glycopyrrolate (Intramuscular, Intravenous) (Advanced Reading)
- Glycopyrrolate (Oral) (Advanced Reading)
Other brands
Robinul, Cuvposa, Robinul Forte, Seebri Neohaler, ... +3 more
Professional resources
- Glycopyrrolate monograph
- Glycopyrrolate Injection (FDA)
- Glycopyrrolate Oral Solution (FDA)
- Glycopyrrolate Tablets (FDA)
Other brands
Robinul, Cuvposa, Seebri Neohaler, Dartisla ODT, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
